Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine
about
Targeted Treatment in Childhood Epilepsy SyndromesLow-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndromeMicroarray Noninvasive Neuronal Seizure Recordings from Intact Larval ZebrafishPharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish.Inhibition of glutamate decarboxylase (GAD) by ethyl ketopentenoate (EKP) induces treatment-resistant epileptic seizures in zebrafish.Voltage-Gated Na+ Channels: Not Just for Conduction.Practical approaches to adverse outcome pathway development and weight-of-evidence evaluation as illustrated by ecotoxicological case studies.Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII).Pharmacogenomics in epilepsy.Serotonergic agents act on 5-HT3 receptors in the brain to block seizure-induced respiratory arrest in the DBA/1 mouse model of SUDEP.Serotonergic modulation as a pharmacological modality in the treatment of Dravet syndromePyridoxine-Dependent Epilepsy in Zebrafish Caused by Aldh7a1 Deficiency.Brain activity patterns in high-throughput electrophysiology screen predict both drug efficacies and side effects.A resurging boom in new drugs for epilepsy and brain disorders.Expanding the Zebrafish Toolkit for Epilepsy Research.Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors.Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening.Zebrafish Models of Neurodevelopmental Disorders: Past, Present, and Future
P2860
Q26751431-66BF6C68-D040-4E5B-8088-6281F89D7768Q26776222-65D96FEA-5CA7-4B36-AFCD-0738074B55CCQ28550179-597E5836-2284-4208-9F57-EE18B27DBC43Q37739145-DC6E49D0-F8E8-4EA8-AE72-7D643EFDB470Q38642231-F6E6D3E3-77A2-45CF-A1CF-96942477A9DEQ38851171-55852DF6-9AEE-4ADD-89A5-9F899A97AC69Q38960807-75A75793-39FE-4522-8A87-A516F43693C2Q39006241-66DB92E4-6DF6-4C3B-85B0-5F06E3312885Q39084353-74A71F71-89DB-426F-AAFB-6AEC91D652AFQ39288824-2F675118-154E-46E1-9C4C-F285EBA26E29Q42243944-F6A39938-DF9D-43F5-93E0-476DDE346449Q47164777-B2B9DD23-28B6-44BD-8A60-354BE246A5FBQ47863623-40BE5E6A-CF7C-43E7-971F-8E4D8D1D163BQ48093388-ED576606-115B-4C25-9B80-C70661172BD3Q55031584-255B4BE6-44F3-4B2B-B94B-6B2F6F08D027Q55340475-0027AE70-6584-458E-978D-73DA34203144Q55471525-48AC69B8-5709-4AC6-8962-737E88C6BD90Q57166914-8049E65D-7472-4A93-B831-9490CE9F8E56
P2860
Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pharmacological characterizati ...... serotonin agonist fenfluramine
@ast
Pharmacological characterizati ...... serotonin agonist fenfluramine
@en
Pharmacological characterizati ...... serotonin agonist fenfluramine
@nl
type
label
Pharmacological characterizati ...... serotonin agonist fenfluramine
@ast
Pharmacological characterizati ...... serotonin agonist fenfluramine
@en
Pharmacological characterizati ...... serotonin agonist fenfluramine
@nl
prefLabel
Pharmacological characterizati ...... serotonin agonist fenfluramine
@ast
Pharmacological characterizati ...... serotonin agonist fenfluramine
@en
Pharmacological characterizati ...... serotonin agonist fenfluramine
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Pharmacological characterizati ...... serotonin agonist fenfluramine
@en
P2093
Alexander D Crawford
Angéla Kecskés
Berten Ceulemans
Lieven Lagae
Mélanie Langlois
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0125898
P407
P577
2015-01-01T00:00:00Z